London Daily

Focus on the big picture.
Thursday, Sep 18, 2025

Britain to infect healthy volunteers with coronavirus in vaccine challenge trials

Britain to infect healthy volunteers with coronavirus in vaccine challenge trials

British scientists said Tuesday they will launch the world's first human challenge trials for covid-19, in which healthy volunteers will be deliberately infected with the coronavirus in hopes of further speeding the drive to a vaccine.

The research, led by scientists at Imperial College London and funded by the British government, is a gutsy gambit, given that people will be submitting themselves to a deadly virus with no surefire treatment.

The United States is moving more cautiously, with leading government researchers saying human challenge trials might be too risky or unnecessary. But the British scientists say the potential payoff is massive — that accelerating vaccine development by even three months could save hundreds of thousands of lives globally.

The British experiment is scheduled to begin in January. Volunteers will have a purified, laboratory-grown strain of the live virus blown into their noses, while quarantined in a 22-bed biosecure unit at the Royal Free Hospital in London, where they will undergo daily, even hourly, tests over two to three weeks.

The initial phase of the study, involving fewer than 100 healthy young adults between ages 18 and 30, will seek to determine the minimal amount of virus necessary to cause an active, measurable infection in their upper respiratory system.

Later in the spring, the scientists hope to enlist more volunteers, who will be inoculated with promising vaccines and then exposed to the virus to see how well the vaccines protect them.

Andrew Catchpole, chief science officer for hVIVO, a commercial pharmaceutical company that will recruit the volunteers, manufacture the challenge strain of the virus and run the challenge trials, told The Washington Post it is not yet known which vaccines will be tested.



The British government has hedged its bets on vaccines still under development, signing an agreement for 100 million doses of a vaccine being tested in trials by Oxford University and AstraZeneca, as well as inking deals with Pfizer, Sanofi and Valneva.

The safety data gained from large Phase 3 trials will still be essential to show the vaccines are ready to be deployed in large populations. But the British government hopes challenge trials will help accelerate the study of vaccines in mid-stages of development and allow for head-to-head comparisons.

Business Secretary Alok Sharma said Tuesday: “The funding announced today for these ground-breaking but carefully controlled studies marks an important next step in building on our understanding of the virus and accelerating the development of our most promising vaccines, which will ultimately help in beginning our return to normal life.”

Christopher Chiu, an Imperial College immunologist who will be one of the lead investigators, said the trials would be able to tell within 10 weeks how effective a coronavirus vaccine is. By contrast, studies that rely on chance exposure, rather than deliberate infection, can take months and tens of thousands of inoculations to prove efficacy.

Challenge experiments have a long history in biomedical research, dating to Edward Jenner’s development of a smallpox vaccine in 1796. In the modern era, challenge trials have been used extensively to study and find treatments for influenza, malaria, typhoid, dengue fever and cholera.

Covid-19, though, is different. Without a medication to reliably “rescue” volunteers from the disease, many scientists are hesitant to infect people.


Danica Marcos, 22, is among the healthy young adults hoping to volunteer in the challenge trials.


Although physicians have more treatments for hospitalized patients than they did at the beginning of the coronavirus pandemic, there isn’t yet an approved drug to stop recently infected people from developing a severe case of covid-19, the disease caused by the virus.

The challenge trial participants will be given the antiviral drug remdesivir, which President Trump took when hospitalized this month for covid-19 and which has been approved or authorized for temporary use to treat covid-19 in more than 50 countries. The World Health Organization, however, recently reported that in large clinical trials in 30 countries, remdesivir had no substantial effect on mortality. That study has not yet been peer-reviewed.

There is also growing evidence that some people develop long-lasting complications from covid-19. But not much is known about how to predict who will go on to be a covid-19 “long-hauler” or how permanent those symptoms are.

“Young people are not immune from that outcome,” Francis Collins, director of the National Institutes of Health, told The Post last week. “Is it actually justifiable to intentionally infect anybody — no matter their current health status? I think that’s a very open question, ethically.”

Nonetheless, more than 38,000 people have indicated a willingness to volunteer by signing up with vaccine advocacy group 1Day Sooner.

“Why? Altruism, basically,” said the group’s petition project manager, Alastair Fraser-Urquhart.

He said for healthy young people like himself, “the risks are low and the potential benefits huge.”

Young people don’t want to be living in world constrained by the pandemic any longer than they must, he said. They also want to help older generations that are more susceptible to serious cases of covid-19 — although some scientists question whether the experience of a healthy 20-something in a challenge trial can predict how an elderly person with high blood pressure would fare.

Fraser-Urquhart suggested volunteers should be paid for their time — maybe $5,000 for a few weeks in quarantine and a year’s worth of follow-up tests.

“There shouldn’t be any out-of-pocket cost, nor should there be financial incentive,” he said.

He added that the British government deserves credit “for going where no one wants to go. Which is to be the first to try.”

If a clinical subject became seriously ill or died in the British challenge trials, the scientists, pharmaceutical companies and the government could be blamed and condemned as reckless. Public support for clinical trials and for new vaccines could also take a hit.

Peter Openshaw, an immunologist at Imperial College London and a co-investigator on the study, said, “Deliberately infecting volunteers with a known human pathogen is never undertaken lightly.”

But, “it is really vital that we move as fast as possible toward getting effective vaccines and other treatments for covid-19, and challenge studies have the potential to accelerate and de-risk the development of novel drugs and vaccines.”

The challenge trial model will be reviewed before launch by a specially convened ethics committee and Britain’s Medicines and Healthcare products Regulatory Agency, its version of the U.S. Food and Drug Administration. Volunteers would then have to sign extensive informed consent documents.

Dominic Wilkinson, a professor of medical ethics at the University of Oxford, noted that volunteers would be increasing their risk but not starting from zero — they would be exposed to a strain of the coronavirus already circulating widely in Britain, especially among young people.

“What is the risk of trial versus the risk of living in London or going to university?” he asked.

With that in mind, he said, the need for human challenge trials is clear.

“You might get a vaccine or you might learn which vaccine is most efficient,” he said, at a time when thousands are dying around the world every day. The worldwide coronavirus death toll has passed 1.1 million.

In the United States, the government has been funding researchers at Colorado State University to develop a potential challenge strain of the coronavirus that could be used if such experiments become necessary.

Creating a challenge strain takes several months, and with several large U.S. vaccine trials projected to reach a decisive milestone that will show whether the vaccines are working by the end of this year or early next year, many scientists said the resource is not likely to be needed.

“My own view is the need for this seems even less likely than it did a few months ago,” said the NIH’s Collins. “The idea of needing to prepare for that was to face the possibility the viral pandemic might actually fade away and there wouldn’t be enough disease spreading in the community.”

Newsletter

Related Articles

0:00
0:00
Close
Nvidia’s $5 Billion Bet on Intel Reshapes AI Hardware Landscape
Trump and Starmer Clash Over UK Recognition of Palestinian State Amid State Visit
Trump’s Quip on Biden and Google Lawsuit Revives Debate Over Antitrust Legacy
Macron and his wife to provide 'scientific photographic evidence' that she is a real woman
US Tech Giants Pledge Billions to UK AI Infrastructure Following Starmer's Call
Saudi Arabia cracks down on music ‘lounges’ after conservative backlash
DeepMind and OpenAI Achieve Gold at ‘Coding Olympics’ in AI Milestone
SEC Allows Public Companies to Block Investors from Class-Action Lawsuits
Saudi Arabia Signs ‘Strategic Mutual Defence’ Pact with Pakistan, Marking First Arab State to Gain Indirect Access to Nuclear Strike Capabilities in the Region
Federal Reserve Cuts Rates by Quarter Point and Signals More to Come
Effective and Impressive Generation Z Protest: Images from the Riots in Nepal
European manufacturers against ban on polluting cars: "The industry may collapse"
Sam Altman sells the 'Wedding Estate' in Hawaii for 49 million dollars
Trump: Cancel quarterly company reports and settle for reporting once every six months
Turkish car manufacturer Togg Enters German Market with 5-Star Electric Sedan and SUV to Challenge European EV Brands
US Launches New Pilot Program to Accelerate eVTOL Air Taxi Deployment
Christian Brueckner Released from German Prison after Serving Unrelated Sentence
World’s Longest Direct Flight China Eastern to Launch 29-Hour Shanghai–Buenos Aires Direct Flight via Auckland in December
New OpenAI Study Finds Majority of ChatGPT Use Is Personal, Not Professional
Hong Kong Industry Group Calls for HK$20 Billion Support Fund to Ease Property Market Stress
Joe Biden’s Post-Presidency Speaking Fees Face Weak Demand amid Corporate Reluctance
Charlie Kirk's murder will break the left's hateful cancel tactics
Kash Patel erupts at ‘buffoon’ Sen. Adam Schiff over Russiagate: ‘You are the biggest fraud’
Homeland Security says Emmy speech ‘fanning the flames of hatred’ after Einbinder’s ‘F— ICE’ remark
Charlie Kirk’s Alleged Assassin Tyler Robinson Faces Death Penalty as Charges Formally Announced
Actor, director, environmentalist Robert Redford dies at 89
The conservative right spreads westward: a huge achievement for 'Alternative for Germany' in local elections
JD Vance Says There Is “No Unity” with Those Who Celebrate Charlie Kirk’s Killing, and he is right!
Trump sues the 'New York Times' for an astronomical sum of 15 billion dollars
Florida Hospital Welcomes Its Largest-Ever Baby: Annan, Nearly Fourteen Pounds at Birth
U.S. and Britain Poised to Finalize Over $10 Billion in High-Tech, Nuclear and Defense Deals During Trump State Visit
China Finds Nvidia Violated Antitrust Laws in Mellanox Deal, Deepens Trade Tensions with US
US Air Force Begins Modifications on Qatar-Donated Jet Amid Plans to Use It as Air Force One
Pope Leo Warns of Societal Crisis Over Mega-CEO Pay, Citing Tesla’s Proposed Trillion-Dollar Package
Poland Green-Lights NATO Deployment in Response to Major Russian Drone Incursion
Elon Musk Retakes Lead as World’s Richest After Brief Ellison Surge
U.S. and China Agree on Framework to Shift TikTok to American Ownership
London Daily Podcast: London Massive Pro Democracy Rally, Musk Support, UK Economic Data and Premier League Results Mark Eventful Weekend
This Week in AI: Meta’s Superintelligence Push, xAI’s Ten Billion-Dollar Raise, Genesis AI’s Robotics Ambitions, Microsoft Restructuring, Amazon’s Million-Robot Milestone, and Google’s AlphaGenome Update
Le Pen Tightens the Pressure on Macron as France Edges Toward Political Breakdown
Musk calls for new UK government at huge pro-democracy rally in London, but Britons have been brainwashed to obey instead of fighting for their human rights
Elon Musk responds to post calling for the murder of Erika Kirk, widow of Charlie Kirk: 'Either we fight back or they will kill us'
Czech Republic signs €1.34 billion contract for Leopard 2A8 main battle tanks with delivery from 2028
USA: Office Depot Employees Refused to Print Poster in Memory of Charlie Kirk – and Were Fired
Proposed U.S. Bill Would Allow Civil Suits Against Judges Who Release Repeat Violent Offenders
Penske Media Sues Google Over “AI Overviews,” Claiming It Uses Journalism Without Consent and Destroys Traffic
Indian Student Engineers Propose “Project REBIRTH” to Protect Aircraft from Crashes Using AI, Airbags and Smart Materials
French Debt Downgrade Piles Pressure on Macron’s New Prime Minister
US and UK Near Tech, Nuclear and Whisky Deals Ahead of Trump Trip
One in Three Europeans Now Uses TikTok, According to the Chinese Tech Giant
×